CHEK1 and head and neck squamous cell carcinoma: Clinical trials with the Chk1 inhibitor SRA737 and the dual Chk1/Chk2 inhibitor prexasertib have been completed for treatment of solid tumors amongst which is HNSCC (NCT01115790, NCT02555644, NCT02797964).